U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Galcanezumab

Last Revision: April 15, 2023.

Estimated reading time: 1 minute

CASRN: 1578199-75-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of galcanezumab during breastfeeding. Because galcanezumab is a large protein molecule with a molecular weight of about 147,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, galcanezumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Migraine Prophylaxis) Divalproex, Erenumab, Metoprolol, Nortriptyline, Propranolol, Rimegepant, Topiramate, Valproic Acid

References

1.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

Substance Identification

Substance Name

Galcanezumab

CAS Registry Number

1578199-75-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK532503PMID: 30372007

Views

Related information

Similar articles in PubMed

  • Review Ravulizumab.[Drugs and Lactation Database (...]
    Review Ravulizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Tildrakizumab.[Drugs and Lactation Database (...]
    Review Tildrakizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Pembrolizumab.[Drugs and Lactation Database (...]
    Review Pembrolizumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Obiltoxaximab.[Drugs and Lactation Database (...]
    Review Obiltoxaximab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Fremanezumab.[Drugs and Lactation Database (...]
    Review Fremanezumab.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...